We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-22.83%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
-$590M
Cap. Flow
-$271M
Cap. Flow %
-26.22%
Top 10 Hldgs %
52.21%
Holding
94
New
6
Increased
10
Reduced
22
Closed
23

Top Buys

Rank Stock Value
1
ARLZ
Aralez Pharmaceuticals Inc.
ARLZ
+$19.6M
2
NVDQ
Novadaq Technologies Inc.
NVDQ
+$18.9M
3
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$18.4M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$14.8M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$7.38M

Top Sells

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$91.5M
2
NVRO
NEVRO CORP.
NVRO
+$31.5M
3
EBS icon
Emergent Biosolutions
EBS
+$26.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$22.9M
5
ATRC icon
AtriCure
ATRC
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 70.61%
2 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHC icon
76
Bausch Health
BHC
$1.65B
– –
-900,000
Closed -$91.5M
BLRX
77
BioLineRX
BLRX
$12.3M
– –
-5,833
Closed -$4.55M
EBS icon
78
Emergent Biosolutions
EBS
$375M
– –
-672,922
Closed -$26.9M
FATE icon
79
Fate Therapeutics
FATE
$281M
– –
-1,113,986
Closed -$3.75M
KALV
80
DELISTED
KalVista Pharmaceuticals
KALV
– –
-84,210
Closed -$4.27M
OSUR icon
81
OraSure Technologies
OSUR
$273M
– –
-685,528
Closed -$4.42M
PTN
82
Palatin Technologies
PTN
$13.7M
– –
-1,094
Closed -$908K
RIGL icon
83
Rigel Pharmaceuticals
RIGL
$680M
– –
-312,528
Closed -$9.47M
TTNP
84
DELISTED
Titan Pharmaceuticals
TTNP
– –
-211
Closed -$3.38M
XBI icon
85
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
– –
-1,000,000
Closed -$70.2M
ALBO
86
DELISTED
Albireo Pharma Inc
ALBO
– –
-66,667
Closed -$685K
AMAG
87
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-300,000
Closed -$9.06M
GNCA
88
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-105,780
Closed -$4.46M
NVDQ
89
CALL
DELISTED
Novadaq Technologies Inc.
NVDQ
– –
-500,000
Closed -$6.37M
STJ
90
DELISTED
St Jude Medical
STJ
– –
-200,000
Closed -$12.4M
AEGR
91
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-500,000
Closed -$5.05M
CYNA
92
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
– –
-583,121
Closed -$8.92M
BDSI
93
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-500,000
Closed -$2.4M
1 2 3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Broadfin Capital held 94 positions worth $1.04B, down 36% from $1.63B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Broadfin Capital withdrew a net $271M in Q1 2016, closing 23 positions and reducing 22 holdings. Its most notable exit was Bausch Health, an estimated $91.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 79% a quarter earlier, followed by Technology.

Against the trend, Broadfin Capital opened a new position in Aralez Pharmaceuticals Inc. worth $13.5M.

  • Broadfin Capital's largest Q1 2016 buy was Aralez Pharmaceuticals Inc.: 3,800,000 shares worth $13.5M.
  • Broadfin Capital added most to Novadaq Technologies Inc. in Q1 2016, an estimated $18.9M increase.
  • Broadfin Capital's biggest Q1 2016 reduction was NEVRO CORP., cutting an estimated $31.5M.
  • Broadfin Capital fully exited Bausch Health in Q1 2016, selling an estimated $91.5M.
  • Broadfin Capital's ten largest holdings make up 52% of its $1.04B portfolio in Q1 2016.
  • Broadfin Capital opened 6 new positions and closed 23 in Q1 2016.
  • Broadfin Capital's portfolio value fell 36% quarter-over-quarter to $1.04B.

Based on Broadfin Capital's 13F filing for Q1 2016, filed 16 May 2016.